A 2026 preprint following 964 adults who used a Chicago mobile medical unit for opioid use disorder care found 5 follow-up patterns over 12 months: 56% made 1 visit, while the remaining patients showed slow decline, fast decline, infrequent use, or continued use.1 Research Highlights The cohort was large for mobile OUD care: 3,528 OUD-related …
A 30-trial meta-analysis found that cholinergic modulators improved schizophrenia negative symptoms, SMD −0.42, while the overall total PANSS/BPRS effect was not statistically significant.1 The clearest signal came from muscarinic agonists, which makes acetylcholine biology promising but not uniformly positive across every cholinergic drug class. Research Highlights Negative symptoms improved: Cholinergic modulators reduced PANSS-N/SANS negative symptom …
A 2026 cross-sectional schizophrenia study found no meaningful association between antipsychotic dose and Montreal Cognitive Assessment (MoCA) performance in young, clinically stable outpatients. Cognitive scores related more strongly to symptom burden, illness duration, education, and age at diagnosis than to daily or 1-year cumulative antipsychotic exposure.1 Research Highlights Daily dose was not linked to MoCA: …
A 2026 national survey of Dutch emergency physicians found wide variation in first-line medication choices for extreme agitation: without intravenous access, 34.7% preferred midazolam, 23.1% preferred droperidol, 14.3% preferred droperidol plus midazolam, and 10.4% preferred esketamine.1 The result is a practice map, not an outcome trial, but it shows how emergency clinicians are balancing rapid …
Restless legs syndrome (RLS) and opioid-withdrawal restlessness both produce night-worsening urges to move. A 2026 npj Parkinson’s Disease mouse study tied that overlap to hypersensitive striatal D1-mu-opioid receptor signaling in basal-ganglia motor circuits.1 Research Highlights 2 clinically similar states converged: restless legs syndrome and opioid-withdrawal restlessness both point toward a striatal D1-mu-opioid circuit that regulates …
Cannabis users often say the drug helps them blunt stressful memories. A 2026 randomized trial of 36 healthy adults tested low-dose oral THC against placebo during retrieval of a standardized lab stressor, and on every subjective and physiological measure that mattered, THC did nothing.1 Research Highlights 36-adult, 3-arm RCT: participants got placebo, 5 mg oral …
A 2026 preclinical study found that 25C-NBF, a selective 5-HT2A psychedelic phenethylamine, increased plasticity-related markers and produced rapid antidepressant-like effects in male rodents, while showing no detected reward or reinforcement signal in the models tested. Research Highlights 25C-NBF was preclinical: Nadal-Gratacos et al. tested cells, male mice, and male rats, not patients with depression.1 5-HT2A …